A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate

P. Casalini, M. Caldera, S. Canevari, S. Ménard, D. Mezzanzanica, E. Tosi, M. Gadina, M. I. Colnaghi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In the attempt to define a strategy for screening new monoclonal antibodies (mAb) that could be appropriate for clinical application in oncology, we evaluated the suitability of three methods: a direct internalization assay (DIA), an indirect internalization assay (IIA) and an indirect cytotoxicity assay (ICA), by applying them to already selected mAb. The latter were directed against three antigenic systems [38-kDa glycoprotein (gp38), epidermal growth factor receptor, and the neu oncogene product], which, according to their tumor selectivity, could be considered suitable for mAb-guided therapy. The dose-dependent and time-dependent binding, as well as the low intraassay variability, demonstrated the reliability of the three tests. However, a certain degree of inter-assay variability was observed in each one, the highest value being that found when IIA was applied. Furthermore, the degree of variability, as well as the predictability, seemed to be more related to the mAb/antigen (Ag) combination used rather than to the test applied. From the overall data we suggest a procedure to be applied for screening purposes. As a first approach applied to the raw material, ICA is only suitable for screening in the case of an already selected toxin whereas IIA may be helpful to eliminate the true negative mAb. After purification of the relevant mAb a repeated analysis using DIA could allow the selection of true internalizing mAb. However, this second screening should be followed by a further analysis of the fate of the Ag-Ab complex after internalization.

Original languageEnglish
Pages (from-to)54-60
Number of pages7
JournalCancer Immunology, Immunotherapy
Volume37
Issue number1
DOIs
Publication statusPublished - Jan 1993

Fingerprint

Immunotoxins
Monoclonal Antibodies
Antigens
Oncogene Proteins
Epidermal Growth Factor Receptor
Glycoproteins

Keywords

  • Internalization assay
  • Monoclonal antibody
  • Tumor-associated antigen

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate. / Casalini, P.; Caldera, M.; Canevari, S.; Ménard, S.; Mezzanzanica, D.; Tosi, E.; Gadina, M.; Colnaghi, M. I.

In: Cancer Immunology, Immunotherapy, Vol. 37, No. 1, 01.1993, p. 54-60.

Research output: Contribution to journalArticle

Casalini, P. ; Caldera, M. ; Canevari, S. ; Ménard, S. ; Mezzanzanica, D. ; Tosi, E. ; Gadina, M. ; Colnaghi, M. I. / A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate. In: Cancer Immunology, Immunotherapy. 1993 ; Vol. 37, No. 1. pp. 54-60.
@article{b4c277ad17dd49e5ac12b48afceadd73,
title = "A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate",
abstract = "In the attempt to define a strategy for screening new monoclonal antibodies (mAb) that could be appropriate for clinical application in oncology, we evaluated the suitability of three methods: a direct internalization assay (DIA), an indirect internalization assay (IIA) and an indirect cytotoxicity assay (ICA), by applying them to already selected mAb. The latter were directed against three antigenic systems [38-kDa glycoprotein (gp38), epidermal growth factor receptor, and the neu oncogene product], which, according to their tumor selectivity, could be considered suitable for mAb-guided therapy. The dose-dependent and time-dependent binding, as well as the low intraassay variability, demonstrated the reliability of the three tests. However, a certain degree of inter-assay variability was observed in each one, the highest value being that found when IIA was applied. Furthermore, the degree of variability, as well as the predictability, seemed to be more related to the mAb/antigen (Ag) combination used rather than to the test applied. From the overall data we suggest a procedure to be applied for screening purposes. As a first approach applied to the raw material, ICA is only suitable for screening in the case of an already selected toxin whereas IIA may be helpful to eliminate the true negative mAb. After purification of the relevant mAb a repeated analysis using DIA could allow the selection of true internalizing mAb. However, this second screening should be followed by a further analysis of the fate of the Ag-Ab complex after internalization.",
keywords = "Internalization assay, Monoclonal antibody, Tumor-associated antigen",
author = "P. Casalini and M. Caldera and S. Canevari and S. M{\'e}nard and D. Mezzanzanica and E. Tosi and M. Gadina and Colnaghi, {M. I.}",
year = "1993",
month = "1",
doi = "10.1007/BF01516942",
language = "English",
volume = "37",
pages = "54--60",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate

AU - Casalini, P.

AU - Caldera, M.

AU - Canevari, S.

AU - Ménard, S.

AU - Mezzanzanica, D.

AU - Tosi, E.

AU - Gadina, M.

AU - Colnaghi, M. I.

PY - 1993/1

Y1 - 1993/1

N2 - In the attempt to define a strategy for screening new monoclonal antibodies (mAb) that could be appropriate for clinical application in oncology, we evaluated the suitability of three methods: a direct internalization assay (DIA), an indirect internalization assay (IIA) and an indirect cytotoxicity assay (ICA), by applying them to already selected mAb. The latter were directed against three antigenic systems [38-kDa glycoprotein (gp38), epidermal growth factor receptor, and the neu oncogene product], which, according to their tumor selectivity, could be considered suitable for mAb-guided therapy. The dose-dependent and time-dependent binding, as well as the low intraassay variability, demonstrated the reliability of the three tests. However, a certain degree of inter-assay variability was observed in each one, the highest value being that found when IIA was applied. Furthermore, the degree of variability, as well as the predictability, seemed to be more related to the mAb/antigen (Ag) combination used rather than to the test applied. From the overall data we suggest a procedure to be applied for screening purposes. As a first approach applied to the raw material, ICA is only suitable for screening in the case of an already selected toxin whereas IIA may be helpful to eliminate the true negative mAb. After purification of the relevant mAb a repeated analysis using DIA could allow the selection of true internalizing mAb. However, this second screening should be followed by a further analysis of the fate of the Ag-Ab complex after internalization.

AB - In the attempt to define a strategy for screening new monoclonal antibodies (mAb) that could be appropriate for clinical application in oncology, we evaluated the suitability of three methods: a direct internalization assay (DIA), an indirect internalization assay (IIA) and an indirect cytotoxicity assay (ICA), by applying them to already selected mAb. The latter were directed against three antigenic systems [38-kDa glycoprotein (gp38), epidermal growth factor receptor, and the neu oncogene product], which, according to their tumor selectivity, could be considered suitable for mAb-guided therapy. The dose-dependent and time-dependent binding, as well as the low intraassay variability, demonstrated the reliability of the three tests. However, a certain degree of inter-assay variability was observed in each one, the highest value being that found when IIA was applied. Furthermore, the degree of variability, as well as the predictability, seemed to be more related to the mAb/antigen (Ag) combination used rather than to the test applied. From the overall data we suggest a procedure to be applied for screening purposes. As a first approach applied to the raw material, ICA is only suitable for screening in the case of an already selected toxin whereas IIA may be helpful to eliminate the true negative mAb. After purification of the relevant mAb a repeated analysis using DIA could allow the selection of true internalizing mAb. However, this second screening should be followed by a further analysis of the fate of the Ag-Ab complex after internalization.

KW - Internalization assay

KW - Monoclonal antibody

KW - Tumor-associated antigen

UR - http://www.scopus.com/inward/record.url?scp=0027232735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027232735&partnerID=8YFLogxK

U2 - 10.1007/BF01516942

DO - 10.1007/BF01516942

M3 - Article

VL - 37

SP - 54

EP - 60

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -